Oral therapies in digestive oncology (Review)
- Authors:
- Caroline Prieux‑Klotz
- Solene Dermine
- Lola‑Jade Palmieri
- Julie Lavole
- Stanislas Chaussade
- Catherine Brezault
- Romain Coriat
-
Affiliations: Department of Hepatology and Gastroenterology, Percy Military Hospital, 92140 Clamart, France, Department of Gastroenterology, Cochin Teaching Hospital, 75014 Paris, France - Published online on: March 20, 2020 https://doi.org/10.3892/or.2020.7555
- Pages: 1719-1728
This article is mentioned in:
Abstract
Bassan F, Peter F, Houbre B, Brennstuhl MJ, Costantini M, Speyer E and Tarquinio C: Adherence to oral antineoplastic agents by cancer patients: Definition and literature review. Eur J Cancer Care (Engl). 23:22–35. 2014. View Article : Google Scholar : PubMed/NCBI | |
Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E and Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 45:291–297. 2000. View Article : Google Scholar : PubMed/NCBI | |
Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, et al: Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer. 105:397–407. 2018.(In French). View Article : Google Scholar : PubMed/NCBI | |
Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, et al: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 28:1638–1644. 2010. View Article : Google Scholar : PubMed/NCBI | |
Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, et al: Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 20:663–673. 2019. View Article : Google Scholar : PubMed/NCBI | |
Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI | |
Grothey A, Sobrero A, Meyerhardt JA, Yoshino T, Paul J, Taieb J, Souglakos I, Kerr R, Labianca R, Shields AF, et al: Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs. 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant Chemotherapy). Ann Oncol. 28 (Suppl 5):v605–v649. 2017. View Article : Google Scholar | |
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, et al: Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial. Lancet. 389:1011–1024. 2017. View Article : Google Scholar : PubMed/NCBI | |
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom, : Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI | |
Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, et al: Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch colorectal cancer group. Lancet. 385:1843–1852. 2015. View Article : Google Scholar : PubMed/NCBI | |
Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J and Kvols L: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 117:268–275. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ikenishi M, Ueda M, Kuroda A, Tsukazaki H, Nakao M, Takeuchi M, Konishi Y, Matsuda T, Figoni W, Ohtori T, et al: A study on drug interaction between warfarin and capecitabine with special reference to the co-administered term or the discontinuation term of capecitabine. Gan To Kagaku Ryoho. 42:833–839. 2015.PubMed/NCBI | |
Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, et al: Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: Secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 3:767–773. 2017. View Article : Google Scholar : PubMed/NCBI | |
Baan J, Bos MMEM, Gonesh-Kisoensingh SU, Meynaar IA, Alsma J, Meijer E and GVulto A: Capecitabine-induced toxicity: An outcome study into drug safety. J Integr Oncol. 3:1132014. View Article : Google Scholar | |
Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 26:2006–2012. 2008. View Article : Google Scholar : PubMed/NCBI | |
Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, et al: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 13:579–588. 2012. View Article : Google Scholar : PubMed/NCBI | |
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015. View Article : Google Scholar : PubMed/NCBI | |
New drug extends lives of brain cancer patients. FDA Consum. 39:32005. | |
Kunz PL, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, Suarez CJ, Yao JC, Kulke MH, Hendifar AE, Shanks JC, et al: A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 36 (15 Suppl):S40042018. View Article : Google Scholar | |
Marx J: Cancer. Encouraging results for second-generation antiangiogenesis drugs. Science. 308:1248–1249. 2005. View Article : Google Scholar : PubMed/NCBI | |
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, et al: Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. Hepatol Res. 50:75–83. 2020. View Article : Google Scholar : PubMed/NCBI | |
Ettrich TJ and Seufferlein T: Regorafenib. Recent Results Cancer Res. 211:45–56. 2018. View Article : Google Scholar : PubMed/NCBI | |
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, et al: Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): A randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 20:1070–1082. 2019. View Article : Google Scholar : PubMed/NCBI | |
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66. 2017. View Article : Google Scholar : PubMed/NCBI | |
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, et al: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:295–302. 2013. View Article : Google Scholar : PubMed/NCBI | |
Grüllich C: Cabozantinib: A MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res. 201:207–214. 2014. View Article : Google Scholar : PubMed/NCBI | |
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, et al: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 379:54–63. 2018. View Article : Google Scholar : PubMed/NCBI | |
Blumenthal GM, Cortazar P, Zhang JJ, Tang S, Sridhara R, Murgo A, Justice R and Pazdur R: FDA approval summary: Sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist. 17:1108–1113. 2012. View Article : Google Scholar : PubMed/NCBI | |
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 364:501–513. 2011. View Article : Google Scholar : PubMed/NCBI | |
George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, et al: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 45:1959–1968. 2009. View Article : Google Scholar : PubMed/NCBI | |
Choi BS: Risks associated with sunitinib use and monitoring to improve patient outcomes. Korean J Intern Med. 29:23–26. 2014. View Article : Google Scholar : PubMed/NCBI | |
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, et al: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet. 378:2005–2012. 2011. View Article : Google Scholar : PubMed/NCBI | |
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, et al: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet. 387:968–977. 2016. View Article : Google Scholar : PubMed/NCBI | |
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 364:514–523. 2011. View Article : Google Scholar : PubMed/NCBI | |
Lombard-Bohas C, Cariou B, Vergès B, Coriat R, N'guyen T, François E, Hammel P, Niccoli P and Hentic O: Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: Expert proposals. Bull Cancer. 101:175–183. 2014.(In French). View Article : Google Scholar : PubMed/NCBI | |
Klümpen HJ, Beijnen JH, Gurney H and Schellens JH: Inhibitors of mTOR. Oncologist. 15:1262–1269. 2010. View Article : Google Scholar : PubMed/NCBI | |
Mesa RA: Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. Biologics. 1:129–138. 2007.PubMed/NCBI | |
Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet. 373:1097–1104. 2009. View Article : Google Scholar : PubMed/NCBI | |
Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, et al: Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: The ACOSOG Z9001 trial. J Clin Oncol. 32:1563–1570. 2014. View Article : Google Scholar : PubMed/NCBI | |
Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, et al: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA. 307:1265–1272. 2012. View Article : Google Scholar : PubMed/NCBI | |
ESMO/European Sarcoma Network Working Group, : Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii21–iii26. 2014. View Article : Google Scholar : PubMed/NCBI | |
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 26:626–632. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M and Judson IR; EORTC Soft Tissue and Bone Sarcoma Group and the Italian Sarcoma Group and Australasian Gastrointestinal Trials Group, : Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 41:1751–1757. 2005. View Article : Google Scholar : PubMed/NCBI | |
Riese C, Weiß B, Borges U Jr, Beylich A, Dengler R, Hermes-Moll K, Welslau M and Baumann W: Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: A cluster-randomized controlled trial. Support Care Cancer. 25:3475–3483. 2017. View Article : Google Scholar : PubMed/NCBI | |
Favier-Archinard C, Leguelinel-Blache G, Cousin C, Gillet C, Bourquard P, Dubois F, Passemard N, Tora S, Rey A, Heraut B, et al: Élaboration d'un guide standardisé d'informations d'optimisation de l'adhésion médicamenteuse à dispenser lors d'une consultation pharmaceutique au patient atteint de myélome multiple: Validation finale. Bull Cancer. 105:1157–1172. 2018. View Article : Google Scholar : PubMed/NCBI | |
Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, et al: Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): A Japanese society for cancer of the colon and rectum multicenter observational study. Oncologist. 23:7–15. 2018. View Article : Google Scholar : PubMed/NCBI | |
Patel AK, Barghout V, Yenikomshian MA, Germain G, Jacques P, Laliberté F and Duh MS: Real-world adherence in patients with metastatic colorectal cancer treated with trifluridine plus tipiracil or regorafenib. Oncologist. 25:e75–e84. 2020. View Article : Google Scholar : PubMed/NCBI | |
Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, et al: 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 27 (Suppl 5):v119–v33. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gebbia V, Carreca I, Testa A, Valenza R, Curto G, Cannata G, Borsellino N, Latteri MA, Cipolla C, Florena M, et al: Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs. 4:443–445. 1993. View Article : Google Scholar : PubMed/NCBI | |
Bryce J and Boers-Doets CB: Non-rash dermatologic adverse events related to targeted therapies. Semin Oncol Nurs. 30:155–168. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lalla RV, Sonis ST and Peterson DE: Management of oral mucositis in patients who have cancer. Dent Clin North Am. 5261–77. (viii)2008. View Article : Google Scholar : PubMed/NCBI |